Therapy of chronic inflammatory bowel diseases. Standards, controversies and perspectives

被引：0
|
作者：
Herrlinger, K. [1 ]
Fellermann, K. [2 ]
Stange, E. F. [3 ]
机构：
[1] Standort Heidberg, Asklepios Klin Nord, Abt Innere Med 1, D-22417 Hamburg, Germany
[2] Univ Klin Schleswig Holstein, Med Klin 1, Bereich Gastroenterol & Hepatol, Lubeck, Germany
[3] Robert Bosch Krankenhaus, Stuttgart, Germany
来源：
INTERNIST | 2014年 / 55卷 / 08期
关键词：
Crohn's disease; Colitis; ulcerative; Azathioprine; Anti-tumor necrosis factor antibodies; Vedolizumab; SEVERE ULCERATIVE-COLITIS; RANDOMIZED CONTROLLED-TRIAL; DIAGNOSED CROHNS-DISEASE; CLINICAL-RESPONSE; CONVENTIONAL MANAGEMENT; COMBINATION THERAPY; MAINTENANCE THERAPY; DOUBLE-BLIND; INFLIXIMAB; AZATHIOPRINE;
D O I：
10.1007/s00108-013-3442-1
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Crohn's disease and ulcerative colitis are the most common forms of chronic inflammatory bowel disease. The therapeutic algorithm is complex and individualized especially in complicated courses of the disease. This article gives a comprehensive overview on the typical courses of disease and the standard therapy of both diseases. Furthermore, ongoing controversies will be highlighted including early immunosuppression and immunomodulation as well as new therapeutic goals, such as mucosal healing. Finally, a perspective on future therapeutic options is given focusing especially on vedolizumab, the new antibody against the bowel-specific alpha 4 beta 7-integrin.
引用
收藏
页码：906 / +
页数：10
相关论文
共 50 条
  • [11] Immunosuppressive drugs in inflammatory bowel diseases.
    Reimund, JM
    Wittersheim, C
    Duclos, B
    Baumann, R
    SEMAINE DES HOPITAUX, 1996, 72 (27-28): : 868 - 879
  • [12] Immunosuppressive drugs in inflammatory bowel diseases.
    Lémann, M
    GASTROENTEROLOGIE CLINIQUE ET BIOLOGIQUE, 1999, 23 (5BIS): : B178 - B188
  • [13] Biological Therapy for chronic inflammatory Bowel Diseases
    Peck-Radosavljevic, Markus
    GASTROENTEROLOGE, 2019, 14 (06): : 469 - 469
  • [14] Fecal lactoferrin is a sensitive and specific marker for chronic inflammatory bowel diseases.
    Kane, S
    Sandborn, WJ
    Rufo, P
    Zholudev, A
    Boone, J
    Lyerly, D
    Camilleri, M
    Hanauer, SB
    GASTROENTEROLOGY, 2001, 120 (05) : A276 - A276
  • [15] Standards, perspectives and limits of the conservative therapy of inflammatory bowel disease
    Rogler, G
    Andus, T
    Scholmerich, J
    ZENTRALBLATT FUR CHIRURGIE, 1998, 123 (04): : 316 - 324
  • [16] Chronic pain and fatigue in inflammatory bowel diseases. How do we handle this?
    Sonnenberg, E.
    Biedermann, L.
    GASTROENTEROLOGE, 2019, 14 (06): : 441 - 450
  • [17] Tumor necrosis factor gene and microsatellite polymorphism in chronic inflammatory bowel diseases.
    Heresbach, D
    Ababou, A
    Bourienne, A
    Alizadeh, M
    Quelvennec, E
    Pagenault, M
    Dabadie, A
    HeresbachLeBerre, N
    Campion, JP
    Launois, B
    Gosselin, M
    Genetet, B
    Bretagne, JF
    Semana, G
    GASTROENTEROLOGIE CLINIQUE ET BIOLOGIQUE, 1997, 21 (8-9): : 555 - 561
  • [18] Intestinal microbiome in chronic diseases. Relevance of gut bacteria in inflammatory bowel diseases and metabolic disorders
    Schueppel, V.
    Haller, D.
    DIABETOLOGE, 2016, 12 (06): : 420 - 427
  • [19] Association of the hSRBC polymorphism with inflammatory bowel diseases.
    Kim, H.
    Hwangbo, Y.
    Shim, J.
    Jang, J.
    Dong, S.
    Kim, B.
    Chang, Y.
    Chang, R.
    INFLAMMATORY BOWEL DISEASES, 2011, 17 : S23 - S23
  • [20] Current medical therapy for chronic inflammatory bowel diseases
    Tamboli, Cyrus P.
    SURGICAL CLINICS OF NORTH AMERICA, 2007, 87 (03) : 697 - +
12345